Replies to post #109531 on Biotech Values

[mcbio]

Maybe. On various message boards, several posters have already scored XL184 as a big win for EXEL and a colossal blunder for BMY—all on the basis of some skimpy results on an endpoint that does not even have a formal definition.

You're presumably just referring to the Phase 2 prostate cancer data that was reported. Any comments on the Phase 2 ovarian cancer data that was reported the same day for XL184 (#msg-56880866)?